• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Transfusion Therapy: Clinical Principles and Practice, 3rd Edition Product Image

Transfusion Therapy: Clinical Principles and Practice, 3rd Edition

  • ID: 2366929
  • October 2010
  • Region: Global
  • 931 Pages
  • AABB

Filling a niche between the handbook and weightier compendia, this edition features the latest discussions and findings in transfusion therapy and provides guidance on how and when to prescribe blood components and derivatives. Enhanced content covers discussions of transfusion therapy in surgery, pediatric transfusion, transfusion-induced immunomodulation, transfusion in stem cell transplantation, and Rh Immune Globulin therapy. The third edition is a must-have for anyone in the field of transfusion medicine.

New this edition:
-Transfusion Therapy in Critical Care.
-Transfusion Therapy in Trauma and Massive Transfusion.
-Pathogen Reduction and Inactivation.
-Alloimmunization to Red Blood Cell Antigens and Management of Alloimmunized Patients.

Chapters cover:
-Clinical practice of transfusion.
-Blood components and derivatives.
-Adverse events.
-Quality in transfusion practice.

Preface
About the Editor
Use of Blood Components in Clinical Practice
1 The Use of Blood Components Prior to Invasive Bedside Procedures: A Critical Appraisal
Jeannie L Callum, MD, FRCP(C), and Walter H Dzik, MD
Prophylactic Use of Blood Components Before Invasive Procedures
Assumptions that Underlie the Prophylactic Use of Blood Components
Specific Bedside Procedures
References
2 Red Cell Transfusion Therapy in Anemia
Jay E Menitove, MD
Oxygen Transport Physiology
Physiologic Compensatory Factors Affecting Oxygen Delivery
Critical Hemoglobin Concentration
Clinical and Experimental Observations in Anemia
Confounding Factors
Conclusion
References
3 Transfusion Therapy in Autoimmune Hemolytic Anemia
Anne F Eder, MD, PhD
Warm Autoimmune Hemolytic Anemia
Cold Autoantibodies and Cold Agglutinin Syndrome
Autoimmune Hemolytic Anemia with Both Warm and Cold Autoantibodies
Paroxysmal Cold Hemoglobinuria
Drug-Induced Immune Hemolytic Anemia
Summary
References
4 Transfusion Therapy in Congenital Hemolytic Anemias
Bruce I Sharon, MD
Hemoglobinopathies and Thalassemias
Disorders of Red Cell Enzymes
Disorders of Red Cell Membranes
Conclusion
References
5 Treatment of Acquired Disorders of Hemostasis
Thomas L Ortel, MD, PhD; Evelyn Lockhart, MD; and John E Humphries, MD
Blood Components and Products
Hemostatic Agents
Acquired Coagulation Disorders
Acquired Coagulation Inhibitors
Conclusion
References
6 Treatment of Congenital Coagulopathies
Roshni Kulkarni, MD; Meera Chitlur, MD; and Jeanne M Lusher, MD
Treatment of Hemophilia A and Hemophilia B
von Willebrand Disease
Other Hereditary Disorders of Blood Coagulation
References
7 Intrauterine, Neonatal, and Pediatric Transfusion Therapy
Edward C C Wong, MD, and Wendy Paul, MD
Fetuses as Transfusion Recipients
Neonates as Transfusion Recipients
Transfusion Beyond the Neonatal Period
Summary
References
8 Transfusion Therapy in Surgery
Richard K Spence, MD, MHA, FACS
Recent Trends
Red Blood Cells in Surgery
Transfusion in Trauma
Risks of Transfusion
Avoidance of Transfusion
Platelets, Fresh Frozen Plasma, and Cryoprecipitate in Surgery
Conclusion
References
9 Massive Transfusion and Transfusion Therapy in Trauma
John R Hess, MD, MPH, FACP, FAAAS; Pär I Johansson, MD, MPA; and
John B Holcomb, MD, FACS
Approach to Severely Injured Patients
The Acute Coagulopathy of Trauma and Shock
Military Surgical Experience
Other Experience and Studies
Who Needs Damage- or Hemorrhage-Control Resuscitation?
The Lack of Level I Evidence
The Need for Better Hemorrhage-Control Products
Massive Transfusion Protocols
Conclusions
References
10 Transfusion Therapy in Critical Care
Thinesh Dahanayake, MD; Patricia Janet Sime, MD, FRCP;
Richard Phipps, PhD; and Neil Blumberg, MD
Causes of Anemia in the ICU
RBC Transfusion in the ICU
Risks of Transfusion
Emergency Transfusions
Decreasing the Need for Transfusion
Platelet Transfusion
FFP Transfusions
Conclusion
References
11 Transfusion Practice in Solid Organ Transplantation
Glenn Ramsey, MD, and Paul D Mintz, MD
Best-Accepted Practices
Transfusion Support
Areas of Interest
Immunohematologic Considerations
Allograft Donor Infectious Disease Testing
References
12 Transfusion Therapy in Therapeutic Apheresis
Gay Wehrli, MD, MSEd
Overview of Therapeutic Apheresis
Therapeutic Apheresis Modalities
Replacement Fluids for Therapeutic Apheresis
Patient Evaluation
Patient Preparation
Procedure Complications
Conclusion
References
Appendix 12-1 Table of Predicted “Normal” Blood Volumes in Men
Appendix 12-2 Table of Predicted “Normal” Blood Volumes in Women
Appendix 12-3 Example of a Therapeutic Apheresis Service Consultation Form
Blood Components and Derivatives
13 Platelet Transfusion Therapy
Deborah Sesok-Pizzini, MD, MBA, and Jay H Herman, MD
Platelet Products
Platelet Refractoriness: Etiology, Prevention, and Management
Indications for Platelet Transfusion
Transfusion Threshold and Prophylactic Transfusion
Assessment and Dose
Selected Adverse Events: Bacterial Contamination, Pathogen Reduction, and
Alloimmunization
Platelet Additive Solutions
Red Blood Cell Transfusion for Thrombocytopenic and Thrombocytopathic
Bleeding
Conclusion
References
14 Granulocyte (Neutrophil) Transfusion Therapy
Ronald G Strauss, MD
Therapeutic Granulocyte (Neutrophil) Transfusions
Prophylactic Granulocyte (Neutrophil) Transfusions
Methods for PMN Collection and Transfusion
References
15 Immune Globulin Therapy
E Richard Stiehm, MD
Animal Sera and Antitoxins
Human Immunoglobulins
Intramuscular Immune Globulin
Intravenous Immunoglobulin
Subcutaneous Immunoglobulin
Advantages and Disadvantages of IGSC
Effectiveness of IGIV or IGSC in Primary Antibody Deficiencies
IGIV or IGSC in Combined Immunodeficiencies
IGIV in Secondary Antibody Deficiencies
Immunoglobulin Therapy in Infection
IGIV in Inflammatory and Autoimmune Disorders
Monoclonal Antibodies
Special Immunoglobulins for Noninfectious Use
Immunoglobulin Use by Unusual Routes
Future Directions
References
16 Rh Immune Globulin
Paul D Mintz, MD
Overview of RhIG Use
Testing and Treatment of Women Who Are Pregnant or Have Been
Pregnant Recently
Antenatal Fetal D Genotyping
Testing the Father
Dose of RhIG
Failure of Prophylaxis
Risks of RhIG Administration
Special Circumstances
Prevention of D Alloimmunization after Transfusion of D-Positive
Red Cells
Conclusion
References
17 Clinical Uses of Fibrin Sealant
William D Spotnitz, MD, MBA
Abdominal Surgery
Cardiovascular Surgery
Dental Surgery
Head and Neck Surgery
Neurosurgery
Obstetric and Gynecologic Surgery
Oncology Surgery (Breast and Inguinal Dissection Procedures)
Ophthalmologic Surgery
Orthopedic Surgery
Plastic Surgery
Thoracic Surgery
Urologic Surgery
Vascular Surgery
Conclusion
References
18 Transfusion Therapy in Hematopoietic Progenitor and Stem Cell Transplantation
Richard C Friedberg, MD, PhD, FCAP, and Chester Andrzejewski, Jr, PhD,
MD, FCAP
Provision of Blood Components
Modifications to Blood Components
Hematopoietic Progenitor Cell Products
Conclusion
References
19 Lymphocytes as Transfusion Immunotherapy
Hanh M Khuu, MD, and Harvey G Klein, MD
Introduction
Lymphocytes, Minimally Manipulated
Lymphocytes, More than Minimally Manipulated
Regulatory Considerations
References
20 The Role of Hematopoietic Growth Factors in Transfusion Medicine
Carolyn F Whitsett, MD
Erythropoiesis Stimulating Agents
Myeloid Growth Factors
Clinical Indications
Thrombopoiesis Stimulating Agents
Conclusion
References
Appendix 20-1 NCCN Guidelines on Myeloid Growth Factors
21 Alloimmunization to Red Cell Antigens and Management of
Alloimmunized Patients
James C Zimring, MD, PhD, and Steven L Spitalnik, MD
Induction of Alloantibodies by Red Cell Transfusion
Management of Alloimmunized Patients
Summary
References
Preventing and Managing Adverse Events
22 Transfusion-Associated Graft-vs-Host Disease
Jed B Gorlin, MD, and Paul D Mintz, MD
History
Clinical Manifestations
Irradiation
General Indications for Irradiation
Which Components May Cause TA-GVHD?
Indications for Irradiating Cellular Blood Components
Alternatives to Irradiation
Conclusion
References
23 Leukocyte-Reduced and Cytomegalovirus-Reduced-Risk
Blood Components
Pamela Clark, MD, JD, and John P Miller, MD, PhD
Leukocyte Reduction: Definition, Mechanisms, Timing, and Potential Adverse
Effects
Febrile Nonhemolytic Transfusion Reactions
Prevention of Alloimmunization and Platelet Refractoriness
Use of Cytomegalovirus-Reduced-Risk Blood Components
Transfusion-Related Immune Modulation
Practical Considerations
Summary
References
24 Alternatives to Allogeneic Transfusion in Patients with Surgical Anemia
Lawrence T Goodnough, MD
Perioperative Autologous Blood Donation and Transfusion
Pharmacologic Interventions to Reduce Allogeneic Blood Transfusion
Conclusion
References
25 Pathogen Reduction Techniques
Joseph P R Pelletier, MD, and Christopher A Tormey, MD
Overview
Solvent/Detergent Treatment
Methylene Blue
Amotosalen
FRALE
PEN110
Riboflavin
Clinical Trials of Pathogen-Reduced Blood Components
Transfusion-Associated Graft-vs-Host Disease
Conclusion
References
26 Management of Transfusion Reactions
Robertson D Davenport, MD
Febrile Nonhemolytic Reactions
Allergic Reactions
Severe Allergic (Anaphylactic) Reactions
Acute Hemolytic Reactions
Delayed Hemolytic Reactions
Bacterial Contamination of Blood Components
Transfusion-Related Acute Lung Injury
Posttransfusion Purpura
Graft-vs-Host Disease
Hypotensive Reactions
Nonimmune Hemolysis
Transfusion-Associated Circulatory Overload
Transfusion-Related Hypothermia
Transfusion-Related Hyperkalemia
Transfusion-Related Acid-Base Abnormalities
Acute Pain Transfusion Reaction
References
Quality in Transfusion Practice
27 Administration of Blood Components
Joanne L Becker, MD
Preadministration Issues
Blood Administration
Current Practices
Conclusion
References
28 Hemovigilance: An Approach to Risk Management in Transfusion Medicine
Cees Th Smit Sibinga, MD, PhD, FRCP Edin, FRCPath, and
Michael F Murphy, MD, FRCP, FRCPath
Overview of Hemovigilance
Public Health Objectives
Transfusion Chain
Transfusion Reactions
Transfusion Quality System
Classification of Adverse Events to Transfusion
Organizational Structure and Levels of Reporting
Use of Data by the French and UK Hemovigilance Systems to Reduce
Adverse Events Associated with Transfusion
Contribution of Hemovigilance to Public Health
Implementation
Most Commonly Encountered Difficulties
Conclusion
References
29 Quality Assessment and Improvement of Blood Transfusion Practices
Paul D Mintz, MD
History
Errors in Transfusion Practice
Accreditation and Regulatory Requirements
The Transfusion Committee
Conclusion
References
30 Overview of Medical-Legal Issues in Transfusion Medicine in the United States
Hon Edward D Bronfin and Pamela Clark, MD, JD
Applicable Legal Principles
Strict Products Liability/Breach of Warranties and Blood Shield Laws
Summary
References
Appendix 30-1 Blood Shield Laws as of May 2010
Summation
31 To Transfuse or Not to Transfuse: An Assessment of Risks and Benefits
Marian Petrides, MD, and James P AuBuchon, MD
Noninfectious Risks of Transfusion
Infectious Risks of Transfusion
Indications for Transfusion

Conclusions
References
Index

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos